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Background: Irisin, a myokine, expressed by muscle and adipose tissue, has been reported to stimulate
conversion of white into brown adipose tissue. The beneﬁcial health effects of exercise are thought to be
mediated in part, via increased production of irisin.
Objective: The primary aim of this study was to assess the association between plasma irisin levels
glycaemic indices in healthy adults. Associations between irisin and lipid levels, CRP and body compo-
sition were explored as secondary outcomes.
Methods: A cross-sectional sample of forty nine (n ¼ 49) free living healthy males (n ¼ 28) and females
(n ¼ 21), between the ages of 18 and 65, with body mass index (BMI) within the healthy range, were
recruited. Body weight, height, and body composition measurements were taken. Fasting blood samples
were collected for the analysis of glucose, insulin and irisin levels. Insulin resistance score, HOMA-IR, was
calculated using fasting blood glucose and insulin values. The relationship between plasma irisin levels
and anthropometric measurements, glucose, insulin and HOMA-IR was determined using Spearman's
bivariate correlation test.
Results: A signiﬁcant inverse relationship was found between plasma irisin levels and
insulin(r ¼ 0.380; P ¼ 0.007) and HOMA-IR(r ¼ 0.362; P ¼ 0.011). This relation was further
strengthened in males when the data was stratiﬁed by gender. Circulating irisin levels were positively
correlated with HDL-C (r ¼ 0.39; P ¼ 0.05) in male participants. Additionally, there was a signiﬁcant
negative correlation between percent body fat (r ¼ 0.43, P < 0.05) and body fat mass (r ¼ 0.47,
P < 0.05) and circulating irisin levels in male participants.
Conclusions: This study reports a sex-dependent inverse relationship between plasma irisin levels and
insulin resistance in healthy subjects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Insulin resistance is the pathological constellation of metabolic
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Inc. This is an open access article uphysical inactivity [1]. The escalating prevalence of insulin resis-
tance worldwide has greatly increased the interest in the metabolic
and physiological role of hormones secreted by muscle [2]. Insulin
resistance, being a component of metabolic syndrome, is a trigger
for pathological conditions like type 2 diabetes and cardiovascular
abnormalities [3,4]. Sedentary lifestyle is a major contributor for
the development of insulin resistance, obesity and type 2 diabetes.
Transient changes in physical inactivity tend to modulate the hor-
mones associated with the metabolic processes leading to the
accumulation of visceral adipose tissue and loss of muscle mass
[5,6]. Scientiﬁc literature in recent years cites skeletal muscle as a
key organ playing an important role in exhibiting resistance or
sensitivity to insulin [2,7]. Advances in research examining the role
of skeletal muscle in insulin resistance has highlighted the secre-
tory function of skeletal muscle, releasing myokines during or postnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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organ suggests it may modify insulin resistance by modulation of
myokines [2,8].
In 2012, Bostrom et al. discovered a novel myokine, irisin,
modulated by peroxisome proliferator activated receptor-g co-
activator 1 (PGC1a) and released upon proteolytic cleavage from
ﬁbronectin type III domain containing protein 5 (FNDC5) [9]. Irisin
is believed to be involved in browning of white adipose tissue and
salutary effects of physical activity [10]. Since the discovery of irisin,
a large volume of literature relating its physiological effects,
browning effect and metabolic function [9,11,12] has been pub-
lished. Administration of irisin through adenoviral delivery system
exhibited browning of white adipose tissue at speciﬁc points
associated with modest but signiﬁcant weight loss [10]. The lower
levels of circulatory irisin have been reported in type 2 diabetes
individuals and positively correlated with age, BMI, cholesterol and
blood pressure in individuals without diabetes [13,14].
Although several studies have been carried out in mice and
humans to determine the therapeutic efﬁcacy of irisin in obesity
and diabetes, there is a need for further research to identify the role
of irisin as a biomarker to predict metabolic disease in healthy
individuals.
The aim of this study was to examine the association between
the plasma irisin levels and glycaemic indices (fasting blood
glucose and insulin levels) along with other metabolic markers,
including lipid levels, CRP, physical activity and body composition
in healthy adults.
2.. Subjects and methods
2.1. Subjects
his was a cross-sectional pilot study including 49 healthy adults
(28 male and 21 female) between the ages of 18e65 years who
were enrolled for an ongoing study. Participants were also asked to
complete a medical questionnaire, International Physical Activity
Questionnaire (IPAQ) and a 3 day food diary. Written consent was
obtained from all the participants. Subjects with diagnosed
hyperlipidaemia, diabetes mellitus, gastrointestinal disorders,
currently on fructose/sugar restricted diet, vegan diet or weight loss
program, who had undergone any surgical procedure for obesity,
pregnant or lactating mothers, currently taking lipid-lowering
drugs, anti-inﬂammatory drugs and BMI >30 kg/m2 were
excluded from the study. Fasting blood samples obtained from the
participants were used to analyse the associations between circu-
lating irisin levels and physical activity, body weight, height and
body composition, blood lipids (triglyceride, LDL-C, HDL-C, Total/
HDL-C), inﬂammation (CRP) and nutrient intake data. The study
protocol was approved by the University of Newcastle Human
Research Ethics Committee.
2.2. Methods
2.2.1. Anthropometry, body composition and nutrient intake
Standing height was measured to the nearest 0.1 cm using a
stadiometer. Body weight, BMI, waist: hip ratio, body fat mass
(BFM) and muscle mass (MM) in the fasting state were measured
using direct segmental multi-frequency bioelectrical impedance
(InBody 230, Biospace Co., Ltd. Seoul, Korea). Participants were
asked to refrain from physical exertion and alcohol consumption
for 24 h prior to testing. Physical activity (metabolic equivalent/
week) was calculated from the International Physical Activity
Questionnaire (IPAQ). 3 day food records were collected. Food re-
cords collected from participants were entered into FoodWorks
Version 7.0.291 database (Xyris Software Pty Ltd, Queensland,Australia) to analyse daily energy and nutrient intake of
participants.
2.2.2. Biochemical analysis
Blood samples were collected into tubes pre-coated with EDTA,
lithium heparin and sodium ﬂuoride by venipuncture. EDTA blood
tubes were centrifuged for 10min at 3000 g at 4 C for separation of
plasma and stored at 80 C for further use. The lithium heparin
tubes for CRP and blood lipids; sodium ﬂuoride tubes for blood
glucose and insulin measurement were analysed by the accredited
Hunter New England Area Pathology Services.
Homeostatic model assessment for insulin resistance (HOMA-
IR), an index of insulin resistance was calculated by using fasting
blood glucose and insulin values as follows: HOMA-
IR¼ (FBG  Insulin)/22.5, where insulin is in lU/mL and fasting
blood glucose is in (mmol/L).
2.2.3. Hormone assays
Irisin levels were measured by competitive Enzyme Linked-
Immunosorbent Assay (ELISA) for quantitative determination of
irisin in human plasma (obtained from centrifugation of EDTA
blood tubes) (Adipogen; Liestal, Switzerland, detection limit 1 ng/
ml). Serum insulin levels were analysed by Hunter New England
Area Pathology services.
2.2.4. Statistical analysis
All data are presented as mean ± SEM. The relationship between
plasma irisin levels and anthropometric measurements, body
composition, glucose, insulin and HOMA-IR was determined using
Spearman's bivariate correlation test. All statistical analyses were
carried out with SPSS software (version 21.0; SPSS Inc., Chicago, IL,
USA). A probability level of p < 0.05 was adopted throughout to
determine statistical signiﬁcance unless otherwise mentioned.
3. Results
3.1. Participant anthropometric characteristics and nutrient intake
Themean age of the all participants was 36.0 ± 1.7 and themean
BMI (kg/m2) was 24.3 ± 0.5 (Table 1). There was no signiﬁcant
difference between the BMI levels of males (25.0 ± 0.57) and fe-
males (23.5 ± 0.8) in this study group. Males had signiﬁcantly
higher levels of skeletal muscle mass (kg) (29.8 ± 1.1 vs 24.5 ± 1.5),
fat free mass (kg) (59.5 ± 1.8 vs 42.1 ± 1.4), but lower levels of
percent body fat (21.1 ± 1.4 vs 30.7 ± 1.8) and body fat mass (kg)
(16.1 ± 1.2 vs 19.0 ± 1.5) than females. The daily energy intake of
males (2121.6 ± 127.0 kcal) was signiﬁcantly higher than females
(1813.4 ± 65.7 kcal). Males consumed signiﬁcantly higher levels of
protein and fat (monounsaturated fat) when compared with the
intake of females (Table 2). Physical activity of the participants was
measured using IPAQ questionnaire. The mean physical activity of
all participants was 1083.8 ± 116.4 MET minutes/week with fe-
males (1198.7 ± 199.7 MET minutes/week) slightly more physically
active than males (997.7 ± 139.0 MET minutes/week).
3.2. Clinical and hormonal characteristics
There were no signiﬁcant differences in clinical characteristics
(Table 1) including glucose (4.8 ± 0.06 vs 4.9 ± 0.08 mmol/L),
cholesterol (5.1 ± 0.18 vs 4.6 ± 0.19 mmol/L), and triglycerides
(1.12 ± 0.11 vs 0.94 ± 0.01 mmol/L) between the male and female
participants. But the LDL-C and total/HDL ratio was signiﬁcantly
higher in male participants (3.23 ± 0.17; 4.2 ± 0.24) than female
participants (2.71 ± 0.18; 3.3 ± 0.22). There were no noteworthy
differences in the levels of irisin and insulin between the males
Table 1
Anthropometric measurements, blood biomarkers & energy and nutrients intakes of study participants.
n
Total Males Females P values
49 28 21
Weight (kg) 67.8 ± 2.2 74.6 ± 2.3 58.7 ± 3.1 <0.05
Age (yrs) 36.0 ± 1.7 37.1 ± 2.4 34.5 ± 2.4 N.S.
BMI (kg/m2) 24.3 ± 0.4 25.0 ± 0.5 23.5 ± 0.7 N.S.
SMM (kg) 29.8 ± 1.1 33.8 ± 1.1 24.5 ± 1.4 <0.05
FFM (kg) 52.0 ± 1.7 59.5 ± 1.8 42.1 ± 1.4 <0.05
PBF (%) 25.1 ± 1.8 21.1 ± 1.3 30.7 ± 1.8 <0.05
BFM 17.3 ± 0.9 16.1 ± 1.2 19.0 ± 1.4 N.S.
Waist: hip 0.9 ± 0.01 0.9 ± 0.01 0.9 ± 0.01 N.S.
Glucose (mmol/L) 4.8 ± 0.06 4.9 ± 0.08 4.8 ± 0.08 N.S.
Cholesterol (mmol/L) 4.9 ± 0.1 5.1 ± 0.1 4.6 ± 0.2 N.S.
Triglyceride (mmol/L) 1.04 ± 0.09 1.1 ± 0.1 0.9 ± 0.1 N.S.
LDL-C (mmol/L) 3.01 ± 0.1 3.2 ± 0.1 2.7 ± 0.1 <0.05
HDL-C (mmol/L) 1.40 ± 0.06 1.3 ± 0.09 1.4 ± 0.08 N.S.
Total/HDL ratio 3.8 ± 0.1 4.2 ± 0.2 3.3 ± 0.2 <0.05
Insulin (mIU/L) 7.5 ± 0.5 7.2 ± 0.7 7.9 ± 0.7 N.S.
CRP (mg/L) 1.6 ± 0.2 1.3 ± 0.2 2.0 ± 0.4 N.S.
HOMA-IR 1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 N.S.
Irisin (mcg/mL) 6.8 ± 0.3 7.1 ± 0.4 6.6 ± 0.4 N.S.
Physical activity (MET-minutes/week) 1084 ± 116 998 ± 139 1199 ± 199 N.S.
Mean values ± Standard Error of Mean.
BMI, Bodymass index; SMM, Skeletal musclemass, FFM, Fat FreeMass; PBF, Percentage Body Fat; BFM, Body fat mass; LDL-C, LowDensity Lipoprotein cholesterol; HDL-C, High
Density Lipoprotein cholesterol; CRP, c-Reactive Protein; HOMA IR Homeostatic model assessment for insulin resistance; N.S., non-signiﬁcant.
The values are represented in bold to highlight the signiﬁcant correlation between the circulating irisin levels and other parameters.
Table 2
Daily energy and nutrient intake of study participants.
Daily intake Total Males Females P values
49 28 21
Energy (kcal) 1990 ± 80 2122 ± 127 1813 ± 66 <0.05
Protein (g) 86 ± 5.1 97 ± 8.0 71.51 ± 4.1 <0.05
Fat (g) 78 ± 4.5 85 ± 6.0 66.21 ± 6.0 <0.05
Saturated Fat (g) 29 ± 1.8 32 ± 2.5 24.62 ± 2.4 N.S.
Polyunsaturated fat (g) 12 ± 0.9 13 ± 1.5 10.42 ± 1.1 N.S.
Monounsaturated fat (g) 28 ± 1.8 31 ± 2.4 23.79 ± 2.6 <0.05
Fibre (g) 25 ± 1.5 25 ± 2.3 23.66 ± 1.9 N.S.
Cholesterol (mg) 274 ± 41 333 ± 63 196 ± 41 N.S.
Carbohydrate (g) 232 ± 11.2 235 ± 18 226 ± 11 N.S.
Sugar (g) 83 ± 5.7 84 ± 8.4 82 ± 7.5 N.S.
F. Jameel et al. / Journal of Nutrition & Intermediary Metabolism 2 (2015) 86e9288(7.10 ± 0.46; 7.2 ± 0.71 mIU/L) and females (6.63 ± 0.41;
7.9 ± 0.78 mIU/L). The HOMA-IR and CRP levels were not signiﬁ-
cantly different between males and females (Table 1).
3.3. Correlation of irisin with physical activity and anthropometric
measurements
The physical activity (MET min/week) data of all study partici-
pants obtained from IPAQ were positively correlated with the
serum irisin levels (r ¼ 0.326, P < 0.05) (Table 3). The correlation
between serum irisin levels and anthropometric measurements
using the Spearman's bivariate correlation test showed gender
differences. There was a signiﬁcant negative correlation between
circulating irisin levels and both percent body fat (r ¼ 0.43,
P < 0.05) and body fat mass (r ¼ 0.47, P < 0.05) in male partici-
pants only (Fig. 3- A & B).
There were no signiﬁcant associations between serum irisin
levels and other anthropometrical parameters (Table 3) including
weight, BMI, SMM, FFM and waist hip ratio, in the total group, or in
males or females alone.
3.4. Correlation of irisin with clinical and hormonal parameters
A signiﬁcant inverse relationship was found between plasma
irisin levels and HOMA-IR (r ¼ 0.29; P ¼ 0.045) and insulin
(r¼0.34; P¼ 0.016) in all study participants (Fig. 1- A&B). Plasmairisin levels were negatively correlated with insulin levels in the
low physically active participants (r ¼ 0.608, p < 0.05) (Table 4).
No signiﬁcant relationship was apparent between irisin and blood
glucose level, triglycerides, cholesterol and CRP (Table 3). When
datawas stratiﬁed intomales and females, the inverse relationships
between plasma irisin levels and HOMA-IR (r ¼ 0.47; P ¼ 0.011)
and insulin (r ¼ 0.46; P ¼ 0.014) were further strengthened in
males (Fig. 2- A&B). Interestingly, irisin level was also found to have
a positive correlation with HDL-C (r ¼ 0.39; P ¼ 0.039) in males
(Fig. 3 e C).
4. Discussion
This is the ﬁrst cross-sectional study to demonstrate an inverse
relationship between plasma irisin levels and insulin or HOMA-IR
scores in healthy individuals. The principal ﬁndings of our study
are the associations between circulating irisin and metabolic pa-
rameters, which are different by sex. The signiﬁcant inverse asso-
ciation between irisin and both insulin and HOMA-IR levels was
evident in males but not females. Interestingly we also found a
signiﬁcant correlation between irisin and HDL-C in male partici-
pants only. Parallel to these observations, plasma irisin levels were
negatively associatedwith percent body fat (PBF) and body fat mass
(BFM) in men but not women. Small sample size in this pilot study
might attribute to difﬁculties in ﬁnding associations between the
irisin and other parameters. The relationship between irisin and
physical activity level appears to be a determinant of the relation-
ship between plasma irisin and fasting insulin levels with a nega-
tive relationship in participants whose physical activity level was
low.
Previous studies involving obese individuals and people with
metabolic syndrome or type 2 diabetes have shown differences in
the association between serum irisin and insulin or HOMA-IR
scores. Some studies have reported a positive correlation [12,15]
while others reported either no correlation [14,16] or even a
negative correlation [17,18] between serum irisin and HOMA-IR
scores. Serum irisin levels were negatively correlated with insulin
and HOMA-IR in our study participants. This might be explained by
the fact that all participants in our study were metabolically
Table 3




r* P r* P r* P
Weight (kg) 0.58 N.S. 0.32 N.S. 0.27 N.S.
BMI (kg/m2) 0.02 N.S. 0.22 N.S. 0.31 N.S.
SMM (kg) 0.12 N.S. 0.02 N.S. 0.29 N.S.
FFM (kg) 0.18 N.S. 0.04 N.S. 0.08 N.S.
PBF (%) 0.16 N.S. ¡0.43 <0.05 0.28 N.S.
BFM 0.17 N.S. ¡0.47 <0.05 0.34 N.S.
Waist: hip 0.03 N.S. 0.09 N.S. 0.17 N.S.
Glucose (mmol/L) 0.07 N.S. 0.12 N.S. 0.29 N.S.
Cholesterol (mmol/L) 0.27 N.S. 0.36 N.S. 0.06 N.S.
Triglyceride (mmol/L) 0.14 N.S. 0.19 N.S. 0.13 N.S.
LDL-C (mmol/L) 0.28 N.S. 0.32 N.S. 0.19 N.S.
HDL-C (mmol/L) 0.23 N.S. 0.39 <0.05 0.02 N.S.
Total/HDL ratio 0.01 N.S. 0.14 N.S. 0.14 N.S.
Insulin (mIU/L) ¡0.34 <0.05 ¡0.46 <0.05 0.09 N.S.
CRP (mg/L) 0.11 N.S. 0.25 N.S. 0.05 N.S.
HOMA-IR ¡0.29 <0.05 ¡0.47 <0.05 0.04 N.S.
Physical activity (MET minutes/week) 0.32 <0.05 0.26 N.S. 0.4 N.S.
r*, Spearman correlation coefﬁcient; Level of signiﬁcance given as P  0.05.
BMI, Bodymass index; SMM, Skeletal musclemass, FFM, Fat FreeMass; PBF, Percentage Body Fat; BFM, Body fat mass; LDL-C, LowDensity Lipoprotein cholesterol; HDL-C, High
Density Lipoprotein cholesterol; CRP, c-Reactive Protein; HOMA-IR, homeostatic model assessment; N.S., non-signiﬁcant; MET metabolic equivalents.
The values are represented in bold to highlight the signiﬁcant correlation between the circulating irisin levels and other parameters.
Fig. 1. Correlation of serum irisin with HOMA IR (A) and insulin (B).
Fig. 2. Correlation of serum irisin with HOMA eIR (A) and insulin (B) in males.
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Fig. 3. Correlation of serum irisin with percent body fat (A), body fat mass (B) and HDL-C (C).
Table 4
Spearman's correlation between irisin and insulin or HOMA-IR in low, moderate and
high physical activity.
Irisin HOMA-IR Insulin
r P r P
Low Phy act (N ¼ 12) 0.538 0.071 ¡0.608* 0.036
Moderate Phy act (N ¼ 27) 0.162 0.421 0.236 0.235
High Phy act (N ¼ 10) 0.212 0.556 0.382 0.276
Phy act e Physical activity; N¼Number of participants; r* spearman correlation
coefﬁcient; Pe signiﬁcance; Category 1¼ Low Individuals who do not meet criteria
for Categories 2 or 3 are considered “low”. Category 2¼Moderate 3 or more days of
vigorous-intensity activity of at least 20 min per day (OR) 5 or more days of
moderate-intensity activity and/or walk of at least 30 min per day (OR) 5 or more
days of any combination of walking, moderate -intensity or vigorous-intensity ac-
tivities achieving a minimum total physical activity of at least 600 MET-minutes/
weeks; Category 3 ¼ High Vigorous-intensity activity on at least 3 days achieving
a minimum Total physical activity of at least 1500 MET-minutes/week (OR) 7 or
more days of any combination of walking, moderate-intensity or vigorous intensity
activities achieving a minimum total physical activity of at least 3000 MET-minutes/
week.
The values are represented in bold to highlight the signiﬁcant correlation between
the circulating irisin levels and other parameters.
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in the normal range. Correlation between irisin and insulin resis-
tance is supported by the hypothesised involvement of the p-38-
PGC1a-irisin-betatrophin pathway [33]. The UCP-1 mediated ac-
tion of irisin promotes the expression of betatrophin and beta cell
regeneration thereby reducing insulin resistance [33]. These results
therefore suggest that irisin may be a sensitive biomarker of insulin
resistance in healthy individuals, however additional studies are
needed to conﬁrm this observations.
Our study demonstrates an association of irisin with insulin or
HOMA-IR, percent body fat, body fat mass and HDL-C with genderdifferences. The differences in the distribution of fat (white and
brown) in males and females might explain the gender differences
[19,20]. Irisin released after exercise induces profound changes in
the subcutaneous adipose tissue to increase the UCP-1 expression
and browning effect [10]. Previous studies reported the expression
of the brown adipocyte marker gene UCP-1 was higher in subcu-
taneous adipose tissue fromwomen thanmen [19]. This hypothesis
might provide a basis for sex based variations in circulating irisin
levels. Another plausible explanation may be the hormonal differ-
ences in males and females. Estradiol, a primary female sex hor-
mone, has been shown to be positively correlated with circulating
irisin levels, while there was no signiﬁcant relationship with free
testosterone levels [12]. Moreover, the skeletal muscle mass (biceps
circumference) has been shown to be positively correlated with
serum irisin levels. Muscle mass is considered to be a main pre-
dictor of circulating irisin concentration underlying its association
with metabolic variables. It has been shown that in male mice,
testosterone induces an increase in energy expenditure derived
from elevated PGC1-amediatedmitochondrial biogenesis, which is
reported to stimulate FNDC5/irisin production in skeletal muscle.
Testosterone levels are known to be several folds higher in men
than pre-menopausal women. The variations in hormonal levels
between males and females might affect the levels of circulating
irisin levels producing gender speciﬁc effects. Hormonal inﬂuences
on the production, secretion and functions of irisin are worthy of
further investigation in order to clarify the observed sex differences
in the association between irisin and insulin or HOMA-IR.
Physical activity level has been identiﬁed as an indicator and
non-pharmacological intervention for prevention of insulin resis-
tance [21,22]. A moderate increase in physical activity has been
correlated with improvements in metabolic proﬁle [23,24], how-
ever the mechanisms underlying the beneﬁcial effects of physical
activity are not clearly understood. Irisin is considered as one of the
F. Jameel et al. / Journal of Nutrition & Intermediary Metabolism 2 (2015) 86e92 91myokines which regulate the beneﬁcial effects of the physical ac-
tivity [10]. Irisin levels have been previously shown to be higher in
young athletes compared to middle aged women [12]. Acute aer-
obic exercise (treadmill running, cycling, sprinting) has been re-
ported to result in elevated irisin levels [25e27]. Consistent with
these studies, a positive correlation between plasma irisin and
physical activity levels has been previously reported [10,12,26].
Notably the inverse relationship between plasma irisin and insulin
or HOMA-IR in the present study is further strengthened when the
data is stratiﬁed on the basis of physical activity levels. Taken
together these results suggest that plasma irisin levels may predict
insulin resistance in physically inactive, but otherwise healthy,
individuals.
A recent review article has highlighted the controversy sur-
rounding the relationship between irisin and anthropometric
measurements [9]. Some previous studies reported a positive cor-
relation of irisin and BMI [12,14] while negative correlations [28,29]
have been described in other studies. In this study, no associations
were observed between circulating irisin levels and anthropo-
metric measurements including body weight, waist to hip ratio and
BMI, which is consistent with the published reports [17,27]. How-
ever, in contrast to the previous studies [12,26], we found an in-
verse relationship of irisin with percent body fat and body fat mass
in males, but not females. The heterogeneity of the data may be due
to the different physiological and experimental conditions and
health status of the individuals. These results can be justiﬁed by the
fact that the participants included in this study were healthy with
no metabolic abnormalities, which differs from the characteristics
of participants from previous studies.
Limited scientiﬁc literature on the relationships between blood
glucose levels and irisin have produced controversial results. Liu
et al. reported a positive correlation between serum irisin and
fasting plasma glucose [14], whereas Choi et al. demonstrated a
negative correlation with OGTT and HbA1c [16]. In the present
study we found there was no signiﬁcant relationship between
glucose, triglycerides and cholesterol levels, which is consistent
with some studies [17,30,31] but not others [12,14,15,32]. The var-
iations in the associations between circulating irisin and metabolic
characteristics like glycaemic proﬁle (glucose and insulin) and lipid
proﬁle (triglycerides and cholesterol) in the present study with
other studies might be explained due to the variation in experi-
mental conditions, differences in the assays used in analysis of irisin
levels, confounding variables like age and gender, physical activity
and the variation in health status of study populations.
Small sample size with a higher number of male participants
might be a limiting factor in the present study. However to our
knowledge, no previous studies have examined the association
between irisin and metabolic parameters in healthy adults, making
it difﬁcult to accurately determine appropriate sample size.
In conclusion, we demonstrate a sex-dependent inverse rela-
tionship between plasma irisin levels and fasting insulin and
HOMA-IR values. The outcomes of this study may be used as a
reference for further studies to determine the role of irisin in the
pathogenesis of insulin resistance using a larger sample size and
including equal number of male and female participants.Funding source
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